Literature DB >> 844897

Antibody-independent activation of the alternative complement pathway in human serum by parasitic cells.

F Kierszenbaum, D Weinman.   

Abstract

The lysis of the monocellular parasite Trypanosoma cyclops by normal human serum (NHS) was found to be complement-dependent and to follow activation of the alternative pathway without apparent requirement for conventional antibodies. Lysis of the organisms was inhibited by heat-inactivating NHS at 56 degrees, preincubation of NHS with cobra venom factor or chelation of divalent cations with EDTA. It took place, however, in human C2-deficient serum and was inhibited by prior heating of NHS at 52 degrees to destroy the activity of factor B of the alternative pathway. Moreover, the lytic reaction was magnesium- but not calcium-dependent. Repeated low-temperature (0 degrees) absorption of either human hypogammaglobulinaemic serum or NHS with the parasite failed to remove or significantly decrease their lytic activities.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 844897      PMCID: PMC1445217     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  9 in total

1.  Destruction of lymphocytes in vitro by normal serum from common laboratory animals.

Authors:  P I TERASAKI; M L ESAIL; J A CANNON; W P LONGMIRE
Journal:  J Immunol       Date:  1961-10       Impact factor: 5.422

2.  Problems of diagnosis of trypanosomasis.

Authors:  D WEINMAN
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

3.  [Lytic effect of normal sera on cultured and sanguineous forms of Trypanosoma cruzi].

Authors:  M RUBIO
Journal:  Bol Chil Parasitol       Date:  1956 Oct-Dec

4.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

5.  Human serum lyses RNA tumour viruses.

Authors:  R M Welsh; N R Cooper; F C Jensen; M B Oldstone
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

6.  Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis.

Authors:  D B Budzko; P J Lachmann; I McConnell
Journal:  Cell Immunol       Date:  1976-03-01       Impact factor: 4.868

7.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  Effects of complement depletion in experimental chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi.

Authors:  D B Budzko; M C Pizzimenti; F Kierszenbaum
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

9.  Studies on the selective lysis and purification of Trypanosoma cruzi.

Authors:  N Nogueira; C Bianco; Z Cohn
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

  9 in total
  8 in total

1.  Humoral bactericidal systems: nonspecific and specific mechanisms.

Authors:  R C Skarnes
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

2.  Experimental bovine trypanosomiasis. Changes in serum immunoglobulins, complement and complement components in infected animals.

Authors:  K Nielsen; J Sheppard; W Holmes; I Tizard
Journal:  Immunology       Date:  1978-11       Impact factor: 7.397

3.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

4.  Immunization of mice with Trypanosoma cruzi polyribosomes.

Authors:  L L Leon; W Leon; L Chaves; S C Costa; M Q Cruz; H M Brascher; A O Lima
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

5.  Requirements of immunoglobulin and the classical and alternative complement pathways for phagocytosis and intracellular killing of multiple strains of Gram-negative aerobic bacilli.

Authors:  P Leist-Welsh; A B Bjornson
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

6.  Activation of the alternative pathway of complement by mycobacteria and cord factor.

Authors:  V D Ramanathan; J Curtis; J L Turk
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

7.  Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.

Authors:  J M Weiler; R W Yurt; D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

8.  Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.

Authors:  M D Kazatchkine; D T Fearon; J E Silbert; K F Austen
Journal:  J Exp Med       Date:  1979-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.